|BWB Ventures||California, Los Angeles, United States|
|Canji Jiaye Touzi||China, Guangdong, Shenzhen|
|Constellation Brands Canada||Canada, Mississauga, Ontario|
|Envision Capital Management||California, Los Angeles, United States|
|Fengwang Investment||China, Shanghai|
|Flywheel Fund||Bloomington, Indiana, United States|
|Jennings Capital Inc||Alberta, Calgary, Canada|
|KOEI TECMO HOLDINGS||Japan, Kanagawa Prefecture, Yokohama|
|Madison Paige Capital||New York, New York, United States|
|Media Future||Japan, Tokyo|
|Microsoft Climate Innovation Fund||-|
|NAV.VC||Reston, United States, Virginia|
|Referentia Systems Incorporated||Hawaii, Honolulu, United States|
|Sun On Investment||China, Guangdong, Guangzhou|
|TCR Capital||France, Ile-de-France, Paris|
|Vignette||Austin, Texas, United States|
|Wille Finance||Switzerland, Zürich, Zurich|
|Yinbaodian Chuangtou||China, Ningbo, Zhejiang|
|Zhidao Capital||China, Jiangsu, Suzhou|
|$33M||27 Jun 2022||Cleveland, Ohio, United States|
|$12M||21 Jun 2022||Columbus, Ohio, United States|
|$30M||05 May 2022||Union City, California, United States|
|$9M||07 Mar 2022||Richfield, Ohio, United States|
|$25M||04 Jan 2022||Sunnyvale, California, United States|
|$1M||08 Nov 2021||Youngstown, Ohio, United States|
|$60M||13 Oct 2021||Columbus, Ohio, United States|
|$3M||06 May 2021||Cincinnati, Ohio, United States|
|01 May 2021||Columbus, Ohio, United States|
– Eikonoklastes Therapeutics from Cincinnati, Ohio develops immunotherapies to treat a broad range of cancers beginning with Triple Negative Breast Cancer (TNBC), a lethal form of breast cancer that comprises 15% of all breast cancers.
– The company raised an undisclosed amount in Series A funding.
– The round was led by CincyTech with participation from New York-based Elk Capital Ventures, Jobs Ohio, Rev1, and other undisclosed investors.
– The new investment will be used to conduct Investigational New Drug (IND) enabling studies for Eikonoklastes Therapeutics’ L-ICON3 immune conjugate platform.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.